These in vitro and in vivo data from cell lines, acquired resistant clones, and patient-derived cells indicated that 35d have potential to inhibit tumor growth in EGFR-mutant LUADs with distinguished TKI-resistance mechanisms, including EGFR C797S mutation. Here, EGFR is linked to neoplasm.